Cascade Screening for Familial Hypercholesterolemia (FH)
Open Access
- 23 May 2011
- journal article
- Published by Public Library of Science (PLoS) in PLoS Currents
- Vol. 3, RRN1238
Abstract
Familial hypercholesterolemia (FH) is an autosomal dominant disorder characterized by abnormally high concentrations of low-density lipoprotein (LDL) cholesterol in the blood, which predisposes affected persons to premature coronary heart disease (CHD) and death. FH is one of the most common inherited disorders and the most common one known to cause premature CHD in people of European descent. The vast majority of people with FH have inherited a single mutation from one parent in either the LDL receptor (LDLR), apolipoprotein B (APOB), or proprotein convertase subtilisin/kexin type 9 (PCSK9) genes. Despite their greatly elevated risk of coronary heart disease, most individuals with FH remain undiagnosed, untreated, or inadequately treated. Cascade screening is a mechanism for identifying people at risk for a genetic condition by a process of systematic family tracing. The National Institute for Health and Clinical Excellence in the United Kingdom recommends cascade screening of close biological relatives of people with a clinical diagnosis of FH in order to effectively identify additional FH patients. The ultimate goal of this testing is to reduce morbidity and mortality from heart disease in persons with FH through early diagnosis and effective disease management. The goal of this article is to outline the available evidence on the clinical validity and utility of cascade screening for FH, while emphasizing the availability, usefulness, and recommendation for including DNA testing (if the disease-causing mutation has been identified).Keywords
This publication has 57 references indexed in Scilit:
- Defining the challenges of familial hypercholesterolemia screening: IntroductionJournal of Clinical Lipidology, 2010
- Integrating provision of specialist lipid services with cascade testing for familial hypercholesterolaemiaCurrent Opinion in Lipidology, 2010
- Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry studyEuropean Heart Journal, 2008
- The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patientsJournal of Internal Medicine, 2004
- Familial Hypercholesterolemia and Coronary Heart Disease: A HuGE Association ReviewAmerican Journal of Epidemiology, 2004
- Genetic Causes of Monogenic Heterozygous Familial Hypercholesterolemia: A HuGE Prevalence ReviewAmerican Journal of Epidemiology, 2004
- Cost effectiveness analysis of different approaches of screening for familial hypercholesterolaemiaBMJ, 2002
- Phenotypic variability in familial hypercholesterolaemia: an updateCurrent Opinion in Lipidology, 2002
- Extent of underdiagnosis of familial hypercholesterolaemia in routine practice: prospective registry studyBMJ, 2000
- Screening for hypercholesterolaemia versus case finding for familial hypercholesterolaemia: a systematic review and cost-effectiveness analysis.Health Technology Assessment, 2000